An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib

NCT02955940 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer
Colorectal Cancer (CRC)
Breast Cancer
Lung Cancer

Interventions

DRUG: Ruxolitinib
DRUG: Capecitabine
DRUG: Regorafenib

Sponsor

Incyte Corporation